701 reports of this reaction
2.2% of all MECLIZINE HCL 12.5 MG reports
#9 most reported adverse reaction
DYSPNOEA is the #9 most commonly reported adverse reaction for MECLIZINE HCL 12.5 MG, manufactured by Advanced Rx LLC. There are 701 FDA adverse event reports linking MECLIZINE HCL 12.5 MG to DYSPNOEA. This represents approximately 2.2% of all 32,440 adverse event reports for this drug.
Patients taking MECLIZINE HCL 12.5 MG who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for MECLIZINE HCL 12.5 MG, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for MECLIZINE HCL 12.5 MG:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 701 FDA reports for MECLIZINE HCL 12.5 MG. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.2% of all adverse event reports for MECLIZINE HCL 12.5 MG, making it a notable side effect.
If you experience dyspnoea while taking MECLIZINE HCL 12.5 MG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.